Me CEO Anne Wojcicki and New Mountain Capital propose $2.53/share buyout to take company private, valuing it at $74.7M after ...
Wojcicki and New Mountain have offered to acquire all of 23andMe's outstanding shares in cash for $2.53 per share, or an ...
Discover the rise and dramatic fall of 23andMe, once a $6 billion genetics pioneer. From revolutionising consumer DNA testing to facing privacy breaches and market shifts, OxStu explores how trust, ...
23andMe is considering a sale of the company as it weighs up strategic options, capping a torrid year for the genetic testing business. A special committee of its directors’ board is considering ...
Ms. Wojcicki, or more exactly the Anne Wojcicki Revocable Trust, is backed in this take-private transaction by New Mountain Capital, with her legal advice from heavyweight law firm Skadden Arps Slate ...
Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial Challenges SUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE ...
23andMe is in need of cash and weighing a sale of the company. The DNA-testing company said Tuesday that it is exploring strategic alternatives, including a business combination and the sale of ...
February is Cancer Prevention Month, and oftentimes when we think about breast cancer, we think about females, but not males.
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year.
Anne Wojcicki’s decision to take 23andMe private with the backing of New Mountain Capital marks a crucial moment in the ...
23andMe CEO Anne Wojcicki and New Mountain Capital have submitted a proposal to take the company private. They are offering to buy all outstanding shares in cash for $2.53 per share, or an equity ...